- Home
- ADCT vs DFDV Comparison
ADCT vs DFDV Comparison
Compare ADCT & DFDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- DFDV
- Stock Information
- Founded
- ADCT 2011
- DFDV 2018
- Country
- ADCT Switzerland
- DFDV United States
- Employees
- ADCT N/A
- DFDV N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- DFDV Finance: Consumer Services
- Sector
- ADCT Health Care
- DFDV Finance
- Exchange
- ADCT Nasdaq
- DFDV Nasdaq
- Market Cap
- ADCT 398.2M
- DFDV 330.2M
- IPO Year
- ADCT 2020
- DFDV N/A
- Fundamental
- Price
- ADCT $3.25
- DFDV $18.18
- Analyst Decision
- ADCT Strong Buy
- DFDV Buy
- Analyst Count
- ADCT 6
- DFDV 1
- Target Price
- ADCT $7.80
- DFDV $45.00
- AVG Volume (30 Days)
- ADCT 545.2K
- DFDV 2.9M
- Earning Date
- ADCT 11-06-2025
- DFDV 11-05-2025
- Dividend Yield
- ADCT N/A
- DFDV N/A
- EPS Growth
- ADCT N/A
- DFDV N/A
- EPS
- ADCT N/A
- DFDV 1.17
- Revenue
- ADCT $77,246,000.00
- DFDV $3,520,660.00
- Revenue This Year
- ADCT $13.10
- DFDV $70.03
- Revenue Next Year
- ADCT $6.23
- DFDV $142.86
- P/E Ratio
- ADCT N/A
- DFDV $15.29
- Revenue Growth
- ADCT 15.73
- DFDV 97.13
- 52 Week Low
- ADCT $1.05
- DFDV $0.49
- 52 Week High
- ADCT $3.97
- DFDV $53.88
- Technical
- Relative Strength Index (RSI)
- ADCT 51.93
- DFDV 54.05
- Support Level
- ADCT $3.15
- DFDV $14.58
- Resistance Level
- ADCT $3.38
- DFDV $18.95
- Average True Range (ATR)
- ADCT 0.18
- DFDV 1.44
- MACD
- ADCT -0.02
- DFDV 0.38
- Stochastic Oscillator
- ADCT 38.53
- DFDV 83.07
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About DFDV DeFi Development Corp. Common Stock
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.